Abstract

Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases. Owing to the ability of these agents to selectively target tumour cells, cancer has been a major focus of development programmes for monoclonal antibodies so far. Here, we overview trends in the clinical development and regulatory approval of monoclonal antibodies for cancer since 1980, with the aim of informing future research and development for this class of therapeutics.

Author affiliations

1. Janice M. Reichert is at the Tufts Center for the Study of Drug Development, Tufts University, 192 South Street, Suite 550, Boston, Massachusetts 02111, USA.
2. Viia E. Valge-Archer is at Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge CB21 6GH, UK.

Correspondence to: Janice M. Reichert¹ Email: janice.reichert@tufts.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.